Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.
It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.
Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.62 Decreased by -67.57% | -0.60 Decreased by -3.33% |
| Aug 8, 24 | -0.56 Decreased by -51.35% | -0.55 Decreased by -1.82% |
| May 15, 24 | -0.51 Decreased by -13.33% | -0.48 Decreased by -6.25% |
| Mar 21, 24 | -0.46 Increased by +11.54% | -0.39 Decreased by -17.95% |
| Nov 9, 23 | -0.37 Increased by +5.13% | -0.40 Increased by +7.50% |
| Aug 10, 23 | -0.37 Increased by +17.78% | -0.44 Increased by +15.91% |
| May 11, 23 | -0.45 Increased by 0.00% | -0.48 Increased by +6.25% |
| Mar 16, 23 | -0.52 Decreased by -6.12% | -0.45 Decreased by -15.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -30.63 M Decreased by -86.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -27.60 M Decreased by -90.53% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -25.05 M Decreased by -69.79% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 4.01 M Increased by +N/A% | -20.89 M Decreased by -40.37% | Decreased by -520.85% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -16.45 M Decreased by -48.50% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -14.49 M Decreased by -13.53% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -14.75 M Decreased by -14.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -14.88 M Decreased by -7.14% | Decreased by N/A% Decreased by N/A% |